{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:33:06Z","timestamp":1791977586464,"version":"4.4.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2004,4]]},"abstract":"\n OBJECTIVE<\/jats:title>\n To describe a serum sickness\u2014like reaction associated with griseofulvin in a child being treated for tinea capitis.<\/jats:p>\n <\/jats:sec>\n \n CASE SUMMARY<\/jats:title>\n A previously healthy 5-year-old boy presented with tactile fever, rash on his legs and back, swelling of his toes and fingers, and leg pain. He was being treated at the time with griseofulvin for tinea capitis. Laboratory evaluation including immunologic workup revealed no abnormalities. Replacement of griseofulvin with itraconazole, along with an antihistamine and a nonsteroidal antiinflammatory drug, led to complete resolution of the patient's symptoms. An objective causality assessment revealed that the adverse reaction was probable.<\/jats:p>\n <\/jats:sec>\n \n DISCUSSION<\/jats:title>\n Serum sickness\u2014like reactions may occur 7\u201321 days following exposure to an offending agent. Clinical manifestations are similar to those of serum sickness, with fever, malaise, and cutaneous eruption. However, on laboratory workup, complement levels are normal. Management of serum sickness\u2014like reaction includes replacing the offending agent and providing symptomatic relief.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n Clinicians should be aware of the possibility of serum sickness\u2014like reaction associated with griseofulvin therapy and consider the possibility when choosing between griseofulvin and newer, more expensive drugs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1345\/aph.1d291","type":"journal-article","created":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T20:44:05Z","timestamp":1078173845000},"page":"609-611","source":"Crossref","is-referenced-by-count":20,"title":["Serum Sickness\u2013Like Reaction Associated with Griseofulvin"],"prefix":"10.1177","volume":"38","author":[{"given":"Roberta L","family":"Colton","sequence":"first","affiliation":[{"name":"Roberta L Colton MD, private practice, Modiin, Israel; volunteer faculty, Department of Pediatrics E, Schneider Children's Medical Center, Petah Tiqva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Amir","sequence":"additional","affiliation":[{"name":"Jacob Amir MD, Department Head, Department of Pediatrics C, Schneider Children's Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Mimouni","sequence":"additional","affiliation":[{"name":"Marc Mimouni MD, Department Head, Department of Pediatrics E, Schneider Children's Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Zeharia","sequence":"additional","affiliation":[{"name":"Avraham Zeharia MD, Head of Day Care Unit, Department of Pediatrics E, Schneider Children's Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2004,4,1]]},"reference":[{"key":"bibr1-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1470.1999.00050.x"},{"key":"bibr2-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1470.2001.01978.x"},{"key":"bibr3-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1989.tb04174.x"},{"key":"bibr4-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6490.249"},{"key":"bibr5-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(89)80031-3"},{"key":"bibr6-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70303-Y"},{"key":"bibr7-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1007\/BF00866733"},{"key":"bibr8-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(87)80275-0"},{"key":"bibr9-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199503000-00010"},{"key":"bibr10-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202600708"},{"key":"bibr11-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000509"},{"key":"bibr12-aph.1D291","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1D291","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:52Z","timestamp":1777374532000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1D291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1345\/aph.1D291"],"URL":"https:\/\/doi.org\/10.1345\/aph.1d291","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}